Document is current
Any future updates will be listed below
-
Authors
Zhou, Yadi
Fang, Jiansong
Bekris, Lynn M.
Kim, Young Heon
Pieper, Andrew A.
Leverenz, James B.
Cummings, Jeffrey
Cheng, Feixiong http://orcid.org/0000-0002-1736-2847
-
Funding
Funding for this research was provided by:
National Institute on Aging (R01AG066707, R56AG063870, P30 AGO62428-01)
National Institutes of Health (P20GM109025)
American Health Assistance Foundation (19PABH134580006)
Foundation for the National Institutes of Health (P20GM109025, U01NS093334, R01AG053798, 3R01AG066707-01S1)
- License Information
-
More Information
Article History
Received: 17 September 2020
Accepted: 23 December 2020
First Online: 13 January 2021
Ethics approval and consent to participate
: Not applicable
: Not applicable
: Dr. Cummings has provided consultation to Acadia, Actinogen, Alkahest, Alzheon, Annovis, Avanir, Axsome, Biogen, BioXcel, Cassava, Cerecin, Cerevel, Cortexyme, Cytox, EIP Pharma, Eisai, Foresight, GemVax, Genentech, Green Valley, Grifols, Karuna, Merck, Novo Nordisk, Otsuka, Resverlogix, Roche, Samumed, Samus, Signant Health, Suven, Third Rock, and United Neuroscience pharmaceutical and assessment companies. Dr. Cummings has stock options in ADAMAS, AnnovisBio, MedAvante, and BiOasis. Dr. Leverenz has received consulting fees from Acadia, Biogen, Eisai, GE Healthcare, and Sunovion. The other authors have declared no competing interest.
